Evidence map›Paper›PMID 28857666›Full record

ReviewHuman vaccines & immunotherapeutics2017

Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations.

Margaret E Gatti-Mays, Jason M Redman, Julie M Collins, Marijo Bilusic

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 65 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
65citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

65 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Molecular Insights into Tumor Immunogenicity.Current issues in molecular biology · 2025
    Article
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. The future of cancer immunotherapy: DNA vaccines leading the way.Medical oncology (Northwood, London, England) · 2023
    Review
  17. Article
  18. Article
  19. Review
  20. Review

5 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Margaret E Gatti-Maysa Medical Oncology Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Jason M Redmana Medical Oncology Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Julie M Collinsa Medical Oncology Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.
Marijo Bilusicb Genitourinary Malignancy Branch , National Cancer Institute, National Institutes of Health , Bethesda , MD , USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic cancer vaccines have gained significant popularity in recent years as new approaches for specific oncologic indications emerge. Three therapeutic cancer vaccines are FDA approved and one is currently approved by the EMA as monotherapy with modest treatment effects. Combining therapeutic cancer vaccines with other treatment modalities like radiotherapy (RT), hormone therapy, immunotherapy, and/or chemotherapy have been investigated as a means to enhance immune response and treatment efficacy. There is growing preclinical and clinical data that combination of checkpoint inhibitors and vaccines can induce immunogenic intensification with favorable outcomes. Additionally, novel methods for identifying targetable neoantigens hold promise for personalized vaccine development. In this article, we review the rationale for various therapeutic combinations, clinical trial experiences, and future directions. We also highlight the most promising developments that could lead to approval of novel therapeutic cancer vaccines.

Indexed as

ImmunomodulationAnimalsAntigens, Tumor-Associated, CarbohydrateCancer VaccinesClinical Trials as TopicCombined Modality TherapyDrug ApprovalGenes, cdcHumansImmunotherapyMiceNeoplasmsPrecision MedicineAntigens, Tumor-Associated, CarbohydrateCancer Vaccinescancer vaccinecombination immunotherapyimmune-related response criteriaimmunogenic modulationimmunotherapy

Identifiers

PMID28857666
PMCPMC5703410

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.